

- 19 **Short title (70 characters):** Designing optimized bacteriology and AMR networks in Kenya
- 20 and Nepal
- 21
- 22

See manuscript DOI for details

²³ **Abstract**

24 Antimicrobial resistance (AMR) is a major global public health concern, particularly in low-25 and middle-income countries (LMICs), which experience the highest burden of AMR. Critical 26 to combatting AMR is ensuring there are effective, accessible diagnostic networks in place to 27 diagnose, monitor and prevent AMR, but many LMICs lack such networks. Consequently, there 28 is substantial need for approaches that can inform the design of efficient AMR laboratory 29 networks and sample referral systems in LMICs. Diagnostic network optimization (DNO) is a 30 geospatial network analytics approach to plan diagnostic networks and ensure greatest access to 31 and coverage of services, while maximizing the overall efficiency of the system. In this study, 32 DNO was applied to strengthen bacteriology and AMR surveillance network design in Kenya 33 and Nepal for human and animal health, by informing linkages between health facilities and 34 bacteriology testing services, and planning of sample referral routes between farms, health 35 facilities and laboratories. Data collected from the target settings in each country were entered 36 into the open-access DNO tool OptiDx, to generate baseline scenarios, which depicted the 37 current state of AMR laboratory networks and sample referral systems in the countries. 38 Subsequently, the baselines were adjusted to evaluate changing factors such as samples flows, 39 transport frequency, transport costs, and service distances. Country stakeholders then compared 40 resulting future scenarios to identify the most feasible solution for their context. The DNO 41 analyses enabled a wealth of insights that will facilitate strengthening of AMR laboratory and 42 surveillance networks in both countries. Overall, the project highlights the benefits of using a 43 data-driven approach for designing efficient diagnostic networks, to ensure better health 44 resource allocation while maximizing the impact and equity of health interventions. Given the combatting AMR is ensuring there are effective, accessible diagnostic networks in place to agnose, monitor and prevent AMR, but many LMICs lack such networks. Consequently, the substantial need for approaches that can info

- 45 critical need to strengthen AMR laboratory and surveillance capacity, DNO should be
- 46 considered an integral part of diagnostic strategic planning in the future.

47 **Abstract word count: 300/300**

- 48
- 49 **Keywords:** diagnostics, laboratory network, antimicrobial resistance, bacteriology,
- 50 surveillance, diagnostic network optimization, sample referral system

See manuscript DOI for details

⁵¹ **Introduction**

71 There are numerous tests to identify infectious agents such as bacteria and fungi and test their 72 susceptibility to different antimicrobial agents. Common methods include Gram staining,

73 culture, biochemical testing and manual antimicrobial susceptibility testing (AST) (11). More 74 modern methods include testing on automated platforms such as the VITEK system, and 75 genomic sequencing (12). However, in many countries these complex devices may only be 76 available at higher tiers of the healthcare network (e.g. at a central laboratory), or may not be 77 available at all in lower-resource settings (13). This is a particular issue in severe and life-78 threatening conditions like sepsis, where the availability of diagnostics is critical, as the risk of 79 death for the patient increases by an estimated 7.6% with every hour that passes before 80 treatment begins (14). 81 As a result, laboratory networks and sample referral systems (SRSs) between national, regional, 82 and peripheral facilities are critical for ensuring accessible and timely diagnostic testing. 83 Efficient and accessible diagnostic laboratories and SRSs at the lower levels of the health 84 system are particularly important for patient care, as healthcare practitioners require timely 85 results from the identification of pathogen and AST to effectively treat patients with the right 86 antimicrobial agent. Such networks are also vital for AMR surveillance, for example, to 87 monitor community outbreaks of multidrug-resistant bacteria and inform disease control 88 activities and treatment prescribing guidelines at a local level. AMR surveillance is typically 89 conducted using bacterial isolates sent via SRSs to higher levels of the network. However, 90 many LMICs do not have organized SRSs for bacteriology testing and AMR surveillance, and 91 patients may be referred to higher levels of the health system to access these services. When 92 they exist, SRSs often are fragmented and not integrated across diseases. In some cases, there 93 may be no access to suitable laboratories for testing. vailable at all in lower-resource settings (13). This is a particular issue in severe and life-
reatening conditions like sepsis, where the availability of diagnostics is critical, as the risk of
eath for the patient incre

94 Strengthening the capacity for bacteriology testing and AMR surveillance in LMICs therefore 95 requires key changes to how testing is handled at all levels of the health system and the

117 networks in both countries, to improve the coverage and efficiency of AMR surveillance. Here,

- 118 we outline the process used to conduct the DNO analysis and key insights generated from this
- 119 novel application of DNO to diagnostic networks for AMR.

120

¹²¹ **Methods**

- 122 In this study, DNO analyses were conducted in Kenya and Nepal between July 2021 and March
- 123 2022 to inform the design of bacteriology and AMR surveillance networks. DNO was
- 124 conducted in line with established methodology (13) and according to each country's context
- 125 and objectives. The study aimed to optimize linkages between health facilities and bacteriology
- 126 testing services at different levels of the health system and assist with the planning of routes for **Alethods**
this study, DNO analyses were conducted in Kenya and Nepal between July 2021 and Marc
222 to inform the design of bacteriology and AMR surveillance networks. DNO was
mducted in line with established methodology

127 referring samples and isolates between farms, health facilities and laboratories.
128

128

129 **Study setting**

130 Kenya's healthcare system is structured across six tiers, starting with community and primary 131 care, up to primary, secondary and tertiary hospitals (22). Primary and secondary hospitals 132 (Levels 4 and 5) offer a wide range of services and receive high volumes of patients referred 133 from lower-level facilities. Kenya is enrolled in the World Health Organization's Global 134 Antimicrobial Resistance and Use Surveillance System (GLASS) and has five AMR 135 surveillance sites participating in the national surveillance system (23). The existing national 136 AMR surveillance strategy focuses on monitoring trends in bacterial resistance to antibiotics, 137 through a network composed of 14 AMR human health laboratories, including the National 138 Microbiology Reference Laboratory (NMRL), located in 13 counties, with plans for expansion

139 to all 47 counties (24). Testing is typically done on-site through walk-in or referred patients, as 140 bacteriology sample referrals for patient management are not in place and only a few isolate 141 referrals exist. Although Kenya has established diagnostic networks and strategic plans for the 142 management of tuberculosis (TB) and HIV (25, 26), existing SRSs for TB and HIV are 143 complex and fragmented, with varied strategies and implementation approaches across donors 144 and implementing partners. 145 In Nepal, the healthcare system is structured across four tiers, comprising community care 146 delivered by community healthcare workers, primary healthcare centres, secondary healthcare 147 facilities (e.g. district hospitals) and tertiary healthcare facilities (e.g. specialized hospitals) 148 (27). The laboratory network in Nepal is tiered, with basic diagnostic services for human health 149 available at most health facilities. Hospital-level facilities may have additional testing capacity, 150 such as instruments for detecting TB drug resistance. Nepal is also enrolled in GLASS and has 151 41 AMR surveillance sites (hospitals with an outpatient department and/or inpatient 152 department), participating in the national surveillance system (23). AMR surveillance in the 153 country started in 1999 with a limited number of participant laboratories and organisms under 154 surveillance (28). The programme has since expanded to a network of 25 human health 155 laboratories plus the National Public Health Laboratory (NPHL) in 2022, covering all seven 156 provinces of the country and seven animal health laboratories located in six provinces. 157 Surveillance networks for human and animal health in the country are separate. Through their mplex and fragmented, with varied strategies and implementation approaches across donors
and implementing partners.
Nepal, the healthcare system is structured across four tiers, comprising community care
elivered by commun

159 among the possible isolates from patients and animals, respectively, through confirmatory

158 respective networks, the NPHL and the Central Veterinary Laboratory (CVL) monitor AMR

160 testing and quality assurance. Currently, Nepal lacks an organized referral system for

161 bacteriology testing and AMR surveillance. As specimens are not always referred, farmers and

- 162 patients directly submit specimens to the nearest laboratory using their own transport system
- 163 and testing is done on-site. Referral of bacterial isolates for confirmatory testing at NPHL and
- 164 CVL is also not commonly practiced. However, Nepal has started to establish active
- 165 surveillance in the animal health sector to strengthen the One Health approach in AMR
- 166 surveillance and response (29), which this project will assist with planning and implementing.
- 167

168 **Objectives and expected outcomes**

169 The main objectives of the DNO analysis were to:

- 173 2. use established country diagnostic networks to model future expansion of referring
- 174 facilities within the network; and
- 175 3. develop optimal sample transport mechanisms for isolates referred from sentinel sites to 176 national reference laboratories to maximize surveillance coverage.
- 177

178 **DNO tool: OptiDx**

179 The DNO analysis was conducted using OptiDx, a web-based, open-access network analytic

- 180 tool, designed for use in LMICs (30). OptiDx models the impact of simultaneously changing
- 181 multiple parameters of network design and performance so multiple scenarios can be compared

- 182 and evaluated. OptiDx is currently in use across LMICs to support DNO analysis for various
- 183 diseases including COVID-19, HIV, TB and human papillomavirus.

184

185 **DNO process**

- 186 A DNO analysis typically comprises five key steps (13). An overview of the process followed
- 187 in Kenya and Nepal for each key step is outlined in Table 1.
- 188
- 189 **Table 1. Key components of DNO process undertaken in Kenya and Nepal**

190

191 **1. Scope of analysis**

192 In both countries, DNO analyses were initiated in 2021, which was considered the "baseline"

- 193 for the AMR and bacteriology networks.
- 194 **Kenya**

196 Antimicrobial Stewardship Interagency Committee (NASIC) and key stakeholders to ensure 197 alignment with the priority needs of the country. Kenya's Ministry of Health requested that the 198 analysis focus on AMR networks for human health only. Stakeholders agreed that the analysis 199 would focus on including AMR within the integrated SRS, which is currently being 200 implemented in the country. As such, the DNO analysis focused on 13 counties with an AMR 201 sentinel surveillance site (shown in Fig. 1a) and covered testing for bacteriology/AMR, TB and 202 HIV. AMR sentinel surveillance sites are usually a hospital laboratory, which can collect 203 specimens, conduct testing and transport isolates to the NMRL and report surveillance data 204 based on AST conducted. Specific tests included in the analysis were: Gram stain, culture, 205 bacterial identification, AST, and quality assurance/confirmatory testing for bacteriology/AMR 206 at NMRL; GeneXpert MTB/RIF and culture/drug susceptibility testing for TB; and early infant

207 diagnosis for HIV. Previous DNO work conducted with Kenya's National TB Programme was 208 also used to inform the current project (31).

209

210 **Nepal**

211 In Nepal, discussions were initiated with government authorities and stakeholders to introduce 212 DNO and OptiDx and understand priorities for AMR surveillance. The most important need 213 identified was to strengthen and institutionalize the referral linkages between sentinel sites and 214 reference laboratories to improve AMR surveillance in human and animal health. Available 215 data on AMR testing and surveillance in Nepal were reviewed to inform the development of a 216 quantified scope of work for the DNO analysis. For animal health, it was agreed that the 217 analysis would include culture, bacterial identification, and AST on samples from poultry 218 species across the geographical scope shown in Fig 1b. For animal health, five out of the seven 219 veterinary laboratories were included, as the two remaining veterinary sentinel sites did not 220 share any data, and 331 farms and slaughterhouses were mapped to those testing sites. 221 For human health, it was agreed that the DNO analysis would cover Bagmati province with its 222 10 AMR human health sentinel sites (Fig 1c). In addition to the bacteriology/AMR programme, 223 the analysis also considered sample referrals for TB and HIV in humans. Specific tests included 224 in the analysis were: Gram stain, culture, bacterial identification, AST, bacterial re-225 identification, confirmatory testing for bacteriology/AMR; GeneXpert MTB/RIF for TB; and 226 viral load testing for HIV. 227 epal.

Nepal, discussions were initiated with government authorities and stakeholders to introduce

NO and OptiDx and understand priorities for AMR surveillance. The most important need

entified was to strengthen and inst

228 **Fig 1.** Geographical scope of DNO analysis

- 229 **a)** in Kenya for human health
- 230 **b)** in Nepal for animal health
- 231 **c)** in Nepal for human health
- 232

233 **2. Collation and preparation of data for analysis**

- 234 In Kenya and Nepal, data templates were developed to collect information and key metrics to
- 235 help evaluate existing bacteriology sample referral and AMR surveillance networks, as of 2021.
- 236 Table 2 outlines the key data that were collected for Kenya and Nepal. Multiple data sources Collation and preparation of data for analysis

Kenya and Nepal, data templates were developed to collect information and key metrics to

elp evaluate existing bacteriology sample referral and AMR surveillance networks, a
- 237 were used to map the 2021 baseline network, including literature review documentation,
- 238 programmatic reports and laboratory datasets.
- 239
-
- 240 **Table 2.** Key data collected to inform DNO analyses in Kenya and Nepal

241 AMR, antimicrobial resistance; AST, antimicrobial susceptibility testing; TB, tuberculosis.

242

243 In Nepal, there were substantial challenges with data availability and quality, notably the non-244 availability of the geocoordinates for health facilities and farms. Geocoordinates of the human 245 health facilities were manually collected using Google Maps, while fictive locations of farms 246 were created using the geographic information system QGIS. The geographic information 247 system (GIS) file of ward distribution was imported into QGIS software to get ward surface 248 areas and coordinates, and a number of farms were assigned to each ward using the random 249 points inside polygon function. Farms were then placed at the centroid of the ward in urban

252

253 **3. Building of baseline model**

261

262 **4. Development of customized optimization scenarios**

263 Based on the baseline analyses and feedback collected from partners, optimization scenarios 264 were created using OptiDx. In the optimized scenarios, current bacteriology and AMR networks 265 were overlayed with existing TB/HIV referral systems to identify gaps and opportunities for 266 specimen referrals and integration across diseases in both countries. Several optimized referral 267 networks were modelled, for samples and isolates referred between farms/health facilities, 268 AMR sentinel sites and national reference microbiology laboratories, and then compared based 269 on costs associated with the deployment of the different SRS designs.

271 **5. Selection and implementation of DNO outputs**

272 Final DNO outputs were presented to the respective Ministries of Health and stakeholders in 273 Kenya and Nepal. Outputs were evaluated to determine the most efficient sample referrals 274 through integrating needs for bacteriology/AMR SRSs with existing systems established for 275 other diseases. DNO allowed stakeholders in Kenya and Nepal to adjust inputs and constraints 276 and weigh up different elements of each scenario to identify the preferred solution for their 277 context. Based on the outputs, a practical guide was developed to support Nepal with setting up 278 and implementing a referral system for the surveillance of human AMR. In Kenya, the 279 recommended county referral systems will be used for the establishment of sample referrals 280 between selected sites and AMR laboratories, and will support the Referral System Technical 281 Working Group in negotiations with contracting courier services to provide sample referral 282 services for all specimens. The integrated sample referral system in Kenya is being 283 implemented at the county level by implementing partners and the counties. Detailed transport 284 costings were also created to support these interventions. rough integrating needs for bacteriology/AMR SRSs with existing systems established for
ther diseases. DNO allowed stakeholders in Kenya and Nepal to adjust inputs and constraints
and weigh up different elements of each sc

²⁸⁵ **Results**

286 Key insights from baseline and optimal network designs for AMR in Kenya and Nepal are 287 described here.

288

289 **Kenya**

290 **Baseline**

307

308 **Future state scenarios & recommendations**

309 In Kenya, 89 Level 4 and 5 hospitals across 13 counties were identified as health facility 310 candidates to be linked with the AMR sentinel sites for sample transportation for patient 311 management. Most hospitals are already connected to the AMR sites, which are county or sub-312 county referral hospitals, through samples referred for rapid TB or HIV molecular testing

334 Kenya (sample referrals from health facilities to AMR sites)

First tier of network:	Scenario 1	Scenario 2	Scenario 3	Scenario 4
Health facility to AMR site	N ₀	Partial	Partial	Integration with
linkages	integration	integration with	integration with	existing TB/HIV
		existing HIV VL	existing TB	referrals
		& EID referrals	GeneXpert	
			referrals	
Percentage of integrated	0%	39%	55%	76%
routes				
Annual distance saved (km)	$\mathbf{0}$	104,716	157,677	210,726
Percentage of annual	0%	30%	44% etalls	59%
distance saved				
Annual transport cost saved	$\mathbf{0}$	\$22,708	\$32,810	\$44,481
(USS)				
Percentage of annual	0%	31%	44%	60%
transport cost saved				

³³⁶ AMR, antimicrobial resistance; EID, early infant diagnosis of HIV; TB, tuberculosis; VL, viral load.

337

338 An example of the recommended SRS for the first tier of the network (sample movements 339 between the hospitals and AMR sentinel sites) is shown in Fig 3 and S1 Table. In the optimized 340 scenario for Bungoma County, Naitiri Sub-County Hospital is linked to the nearest AMR site, 341 which is Kitale County Referral Hospital in Trans Nzoia County. The optimized scenario 342 creates opportunities for transport cost savings through using existing TB and HIV referrals. 343

344

346 **Fig 3.** Recommended bacteriology sample referral system in Bungoma County

347

348

366 Kenya (AMR isolate referrals to the National Microbiology Reference Laboratory)

367 AMR, antimicrobial resistance; C/DST, culture/drug susceptibility testing; NMRL, National Microbiology white DOI for details

368 Reference Laboratory; TB, tuberculosis.

369

370 A costing analysis was performed to evaluate the cost of implementing the recommended SRSs, 371 using data that were provided by the county authorities and assumptions defined with NASIC 372 on a number of elements (including transport modes, distance travelled, transport frequency, 373 referral routes). When estimating the cost of moving samples from point A to B and excluding 374 other cost elements such as human resources, packaging, supplies and documentation, the 375 estimated annual transport cost was US\$ 73,987 for the first tier of the network and US\$ 16,580 376 for the second tier (S3 Table).

377

378 **Nepal: animal health**

379 **Baseline**

380 Between January and December 2021, a total of 3549 bacteriology and AST tests on faecal,

381 caecal and tissue samples from poultry species in five laboratories were conducted in Nepal;

402 CVL, Central Veterinary Laboratory; NAL, National Avian Disease Investigation Laboratory.

404 **b)** Hub-spoke model for Janakpur laboratory

405

418 **Table 5.** Estimated annual transport cost for the network from hub to regional labs and labs to 419 CVL

420 CVL, Central Veterinary Laboratory; MAD, maximum allowable distance.
421 CM USC

421

422

423

424 **Nepal: human health**

425 **Baseline**

426 Between January and December 2021, 180,404 bacteriology and AST tests were performed in

427 10 laboratories for human health and culture tests accounted for 61% of total bacteriological

428 testing demand. For human health, just two out of 10 human health sentinel sites drove almost

429 half (48 %) of the bacteriology testing. The average utilization across devices was 29%, with

430 significant variations across laboratories (from 3% to 72%).

431 **Future state scenarios & recommendations**

449

450 AMR, antimicrobial resistance; NPHL, National Public Health Laboratory; TB, tuberculosis; VL, viral 451 load.

452 The recommended direct-to-lab isolate referral system is shown in Fig 7.

- **Fig 7. Recommended bacterial isolate referral system for human health in Nepal:**
- **Direct to lab**
- **a)** Outside Kathmandu Valley
- **b)** Kathmandu Valley See manuscript DOI for details

⁴⁵⁹ **Discussion**

460 In this study, the application of DNO created a wealth of insights into the bacteriology and 461 AMR surveillance networks in Kenya and Nepal, and enabled the design of efficient and cost-462 effective diagnostic networks adapted to each country's settings and priorities. Specifically, the 463 analysis highlighted key gaps and opportunities to inform the design of specimen referrals in 464 both countries. Findings from the DNO analysis also provided evidence for establishing 465 optimized sample and isolate referral networks and informed the development of an operational 466 guide for AMR isolate referrals in Nepal. Furthermore, the analyses highlighted the potential 467 for leveraging existing TB/HIV networks for bacteriology sample and isolate referrals in Kenya
468 and Nepal for human health.
468 468 and Nepal for human health. Tective diagnostic networks adapted to each country's settings and priorities. Specifically, the altimative distribution of specifical settings in the countries. Findings from the DNO analysis also provided evidence for es

469 While DNO has been successfully applied to optimize diagnostic networks for other diseases 470 like TB and HIV (18, 20, 21), this was the first large-scale application of DNO to AMR. The 471 critically high burden of AMR in LMICs carries dire consequences for the health of people and 472 animals in such settings, as drug-resistant organisms spread throughout the environment and 473 between countries. Strengthening diagnostic networks and surveillance systems is key to 474 tackling growing rates of AMR (3, 5), and as such, DNO offers lower-resource countries an 475 evidence-based, open-access approach to optimize their diagnostic networks. As scaling up 476 surveillance laboratories is a timely and costly endeavour, DNO can help design and optimize 477 specimen/isolate referral systems to increase access to testing and improve surveillance in the 478 shorter term in resource-limited settings.

479 Findings from the analyses are being used to guide decision-makers in Kenya and Nepal in 480 budgeting and action planning for the implementation of the recommended referral systems. In

481 Kenya, the national SRS technical working group is currently engaging an external provider to 482 provide sample referral services for all specimens, and the DNO outputs will be used to support 483 the design and implementation of the integrated model. In Nepal, the recommended referral 484 network design, proposed route maps and operational guidance will be used to establish a 485 strong and sustained isolate referral network for human health and animal health. 486 The DNO analyses in Kenya and Nepal also provided a number of learnings and considerations 487 that can be used to guide future applications of DNO to AMR. Firstly, when working on AMR 488 laboratory networks, it is important to consider that AMR programmes are often relatively new 489 in LMICs compared with other more established national disease programmes like TB and 490 HIV. In this study, DNO was a new concept to the national AMR programmes, which meant 491 the benefits of the approach and specific outputs that countries could use had to be 492 communicated clearly to stakeholders who were unfamiliar with the process. 493 Early engagement with the country stakeholders was therefore important to align partners on 494 the objectives of and benefits from DNO upfront, and drive engagement with the project. Work 495 was undertaken to highlight the benefits of DNO for the AMR programmes and define scopes 496 for the analyses that took the local context and national priorities into account, to make sure 497 outputs were impactful and useful. Early engagement was also important to identify and address 498 any capacity building needs that stakeholders may have had around conducting a DNO analysis. 499 Building the capacity of the national AMR programmes and key stakeholders around DNO is 500 important to enable an inclusive and country-owned process and ensure that implementable 501 outputs are prioritized during the process. For settings where geospatial analysis is a new 502 concept, an initial laboratory mapping exercise may also be beneficial to secure interest in DNO rong and sustained isolate referral network for human health and animal health.
he DNO analyses in Kenya and Nepal also provided a number of learnings and consideration
at can be used to guide future applications of DNO to

503 and give stakeholders the skills to evaluate network designs and refine questions to be

504 addressed by the full DNO analysis.

505 This study also highlights that newer programmes like AMR should utilize data-driven strategic 506 planning to design diagnostic networks as early as possible, to reduce network inefficiencies, 507 avoidable costs, and challenges with access and coverage from the start. Utilizing DNO enables 508 the deployment of diagnostic networks based on need for services rather than geographic or 509 administrative considerations.

510 Another key consideration when conducting any DNO analysis is that the availability and 511 quality of data significantly affect the resources needed and timelines for conducting a DNO, as 512 well as outcomes of the analysis. Therefore, before undertaking any analysis, it is essential to 513 ascertain that key data inputs, such as geocoordinates of health facilities and testing sites, are 514 available. In terms of AMR specifically, the nature of bacteriology and AMR networks may 515 also present some challenges compared with other disease-specific diagnostic networks such as 516 TB/HIV. In particular, defining tests, testing capacity, device-test combinations and estimating 517 test costs can be challenging, as bacteriology testing comprises a sequence of different steps 518 than cannot be separated from each other. In addition, an important component of bacteriology 519 and AST testing is manual testing (e.g. culture), which is more difficult to model than machine-520 based testing. Furthermore, as DNO is most effective when embedded in planning/funding 521 cycles, a DNO analysis needs to be conducted at an appropriate time, when insights from the 522 analysis can contribute to the development of evidence-based national strategic plans, funding 523 requests, resource allocation, or procurement and operational planning. animg to usign unglibstic networks as carry as possible, to reduce network inemetencies,
voidable costs, and challenges with access and coverage from the start. Utilizing DNO enable
deployment of diagnostic networks based

524 Finally, it is important to note that the value and impact of a DNO analysis will ultimately

525 depend on whether the suggested interventions are adopted and how well they are implemented

526 and monitored. Consequently, plans should be in place to support the practical implementation

527 of interventions and for the monitoring and evaluation of interventions once established.

528 Application of DNO to AMR also presents opportunities to address other potential questions

529 and topics that may be of interest in the future, including sequencing capacity placement, how

- 530 best to support AMR surveillance efforts, and where diagnostic network capacity for
- 531 bacteriology and AST could be integrated with testing for other diseases to increase access and

532 efficiency.

533 Limitations of this study largely related to the availability of data for the DNO. In Nepal, the 534 analysis was limited in geographic scope as much of the data need for a countrywide analysis 535 (e.g. geocoordinates, laboratory data) were not available. Some of the approaches utilized to 536 overcome data issues included using approximate farm locations, estimating annual data for 537 2021 using quarterly/biannual data, and modelling testing capacity. These factors could have 538 affected the precision of the recommended network designs in Nepal, but provided stakeholders 539 with an initial analysis that would have not been available otherwise. est to support AMR surveillance efforts, and where diagnostic network capacity for
acteriology and AST could be integrated with testing for other diseases to increase access and
ficiency.
imitations of this study largely r

540 Overall, the project highlights the benefits of using a data-driven approach for designing

541 efficient diagnostic networks, to ensure better health resource allocation while maximizing the

542 impact and equity of health interventions. Given the critical need to strengthen AMR laboratory

543 and surveillance capacity, network mapping and optimization should be considered an integral

544 part of diagnostic strategic planning in the future.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.11.03.22281886;](https://doi.org/10.1101/2022.11.03.22281886) this version posted November 5, 2022. The copyright holder for this preprint

⁵⁴⁵ **Acknowledgements**

546 The authors would like to thank André Trollip, FIND, for his technical support on the AMR 547 laboratory testing and costing, Kinuthia Bubi, FIND, for support with project coordination and 548 administrative support, and Dr Runa Jha and Lilee Shrestha from NPHL Nepal for their support 549 to carry out this study. Medical writing support was provided by Talya Underwood, MPhil, of 550 Anthos Communications Ltd, UK, funded by FIND, according to Good Publication Practice 551 guidelines. Iministrative support, and Dr Runa Jha and Lilee Shrestha from NPHL Nepal for their support
carry out this study. Medical writing support was provided by Talya Underwood, MPhil,
nthos Communications Ltd, UK, funded by FIND

552

⁵⁵³ **Data sharing statement**

554 The minimal dataset has been uploaded in the Supporting Information files. Data requests should 555 be directed to Dr Tulsi Gompo, Central Veterinary Laboratory, Nepal, (contact via 556 tulsigompo@gmail.com), to Jyoti Acharya, National Public Health Laboratory, Nepal, (contact 557 via jyotigan30@gmail.com), to Dr Evelyn Wesangula, National Antimicrobial Stewardship 558 Interagency Committee, Kenya (contact via wesangulaeva@gmail.com). All other underlying 559 data are provided in the manuscript and/or the Supporting Information files.

560

⁵⁶¹ **Funding**

562 This work was funded by the Department of Health and Social Care's Fleming Fund using UK

563 aid. The views expressed in this publication are those of the authors and not necessarily those of

564 the UK Department of Health and Social Care or its Management Agent, Mott MacDonald.

565

⁵⁶⁶ **Contributors**

- 567 Conceptualization: Heidi Albert, Cecilia Ferreyra, Nada Malou
- 568 Data curation: Marie Brunetti, Amit Singh
- 569 Formal analysis: Marie Brunetti, Amit Singh, Sheilla Chebore
- 570 Funding acquisition: Heidi Albert, Cecilia Ferreyra
- 571 Investigation: Marie Brunetti, Sheilla Chebore, Deepak Gyenwali, Nisha Rijal, Amit Singh
- 572 Methodology: Heidi Albert, Marie Brunetti, Amit Singh
- 573 Project administration : Heidi Albert, Marie Brunetti, Cecilia Ferreyra, Deepak Gyenwali, Nada 574 Malou ata curation: Marie Brunetti, Amit Singh

ormal analysis: Marie Brunetti, Amit Singh, Sheilla Chebore

unding acquisition: Heidi Albert, Cecilia Ferreyra

uvestigation: Marie Brunetti, Sheilla Chebore, Deepak Gyenwali, Nis
- 575 Supervision: Heidi Albert, Jyoti Acharya, Cecilia Ferreyra, Susan Githii, Tulsi Gompo, Nada
- 576 Malou, Evelyn Wesangula
- 577 Validation: Heidi Albert, Marie Brunetti, Jyoti Acharya, Susan Githii, Sheilla Chebore, Tulsi
- 578 Gompo, Amit Singh, Evelyn Wesangula
- 579 Visualization: Heidi Albert, Marie Brunetti, Amit Singh
- 580 Writing original draft: Heidi Albert, Marie Brunetti
- 581 Writing review & editing: Heidi Albert, Jyoti Acharya, Marie Brunetti, Sheilla Chebore, Cecilia
- 582 Ferreyra, Susan Githii, Tulsi Gompo, Deepak Gyenwali, Nada Malou, Nisha Rijal, Amit Singh,
- 583 Evelyn Wesangula
- 584

⁵⁸⁵ **Declaration of interests**

594

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.11.03.22281886;](https://doi.org/10.1101/2022.11.03.22281886) this version posted November 5, 2022. The copyright holder for this preprint

⁵⁹⁶ **References**

597

- 599 https://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance.
- 600 2. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations:
- 601 Government of the United Kingdom; 2016.
- 602 3. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial
- 603 resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55.
- 604 4. Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al.

605 Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered tps://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance

O'Neill J. Tackling drug-resistant infections globally: final report and recommendation

overnment of the United Kingdom; 2016.

Antimicrobial Res

606 picture. Antimicrobial Resistance & Infection Control. 2021;10(1):63.

607 5. Sulis G, Sayood S, Gandra S. Antimicrobial resistance in low- and middle-income

608 countries: current status and future directions. Expert Rev Anti Infect Ther. 2022;20(2):147-60.

609 6. Yadav H, Shah D, Sayed S, Horton S, Schroeder LF. Availability of essential

610 diagnostics in ten low-income and middle-income countries: results from national health

611 facility surveys. The Lancet Global Health. 2021;9(11):e1553-e60.

- 612 7. Leslie HH, Spiegelman D, Zhou X, Kruk ME. Service readiness of health facilities in
- 613 Bangladesh, Haiti, Kenya, Malawi, Namibia, Nepal, Rwanda, Senegal, Uganda and the United
- 614 Republic of Tanzania. Bull World Health Organ. 2017;95(11):738-48.

- 615 8. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of
- 616 Antibiotic Resistance Transmissionin Low- and Middle-Income Countriesfrom a "One Health"
- 617 Perspective-A Review. Antibiotics (Basel). 2020;9(7).
- 618 9. Sulis G, Adam P, Nafade V, Gore G, Daniels B, Daftary A, et al. Antibiotic prescription
- 619 practices in primary care in low- and middle-income countries: A systematic review and meta-
- 620 analysis. PLoS Med. 2020;17(6):e1003139.
- 621 10. Do NTT, Vu HTL, Nguyen CTK, Punpuing S, Khan WA, Gyapong M, et al.
- 622 Community-based antibiotic access and use in six low-income and middle-income countries: a
- 623 mixed-method approach. The Lancet Global Health. 2021;9(5):e610-e9.
- 624 11. Giuliano C, Patel CR, Kale-Pradhan PB. A Guide to Bacterial Culture Identification Suis G, Adam 1, Islande V, Gote G, Damels B, Danaly A, et al. Almoholic presemption
actices in primary care in low- and middle-income countries: A systematic review and meta-
allysis. PLoS Med. 2020;17(6):e1003139.
Do NTT,
- 625 And Results Interpretation. P t. 2019;44(4):192-200.
- 626 12. van Belkum A, Bachmann TT, Lüdke G, Lisby JG, Kahlmeter G, Mohess A, et al.
- 627 Developmental roadmap for antimicrobial susceptibility testing systems. Nature Reviews
- 628 Microbiology. 2019;17(1):51-62.
- 629 13. FIND. Diagnostic network optimization: A network analytics approach to design
- 630 patient-centred and cost-efficient diagnostic systems 2021 [Available from:
- 631 [https://www.finddx.org/wp-content/uploads/2021/11/Guide-to-Diagnostic-Network-](https://www.finddx.org/wp-content/uploads/2021/11/Guide-to-Diagnostic-Network-Optimization_15.11.2021.pdf)
- 632 [Optimization_15.11.2021.pdf](https://www.finddx.org/wp-content/uploads/2021/11/Guide-to-Diagnostic-Network-Optimization_15.11.2021.pdf).
- 633 14. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of
- 634 hypotension before initiation of effective antimicrobial therapy is the critical determinant of
- 635 survival in human septic shock. Crit Care Med. 2006;34(6):1589-96.

- 637 <https://www.who.int/news-room/questions-and-answers/item/one-health>.
- 638 16. Nichols K, Girdwood SJ, Inglis A, Ondoa P, Sy KTL, Benade M, et al. Bringing Data
- 639 Analytics to the Design of Optimized Diagnostic Networks in Low- and Middle-Income
- 640 Countries: Process, Terms and Definitions. Diagnostics (Basel). 2020;11(1).
- 641 17. Albert H, Purcell R, Wang YY, Kao K, Mareka M, Katz Z, et al. Designing an
- 642 optimized diagnostic network to improve access to TB diagnosis and treatment in Lesotho.
- 643 PLOS ONE. 2020;15(6):e0233620.
- 644 18. Girdwood SJ, Nichols BE, Moyo C, Crompton T, Chimhamhiwa D, Rosen S.

645 Optimizing viral load testing access for the last mile: Geospatial cost model for point of care Maryles to the Design of Opininzed Diagnostic Networks in Low- and Middle-Income

ountries: Process, Terms and Definitions. Diagnostics (Basel). 2020;11(1).

7. Albert H, Purcell R, Wang YY, Kao K, Mareka M, Katz Z, et al.

646 instrument placement. PLOS ONE. 2019;14(8):e0221586.

647 19. Kiyaga C, Sendagire H, Joseph E, McConnell I, Grosz J, Narayan V, et al. Uganda's

648 New National Laboratory Sample Transport System: A Successful Model for Improving Access

649 to Diagnostic Services for Early Infant HIV Diagnosis and Other Programs. PLOS ONE.

650 2013;8(11):e78609.

651 20. Nichols BE, Girdwood SJ, Crompton T, Stewart-Isherwood L, Berrie L, Chimhamhiwa

652 D, et al. Impact of a borderless sample transport network for scaling up viral load monitoring:

- 653 results of a geospatial optimization model for Zambia. J Int AIDS Soc. 2018;21(12):e25206.
- 654 21. Robin TA, Khan MA, Kabir N, Rahaman ST, Karim A, Mannan, II, et al. Using spatial

655 analysis and GIS to improve planning and resource allocation in a rural district of Bangladesh.

- 656 BMJ Glob Health. 2019;4(Suppl 5):e000832.
- 657 22. Republic of Kenya Ministry of Health. Kenya Health Policy 2014–2030. 2014.

- 658 23. World Health Organization. Global Antimicrobial Resistance and Use Surveillance
- 659 System (GLASS) Report: 2021. 2021.
- 660 24. Government of Kenya. National Action Plan for the Prevention and Containment of
- 661 Antimicrobial Resistance. 2017.
- 662 25. Republic of Kenya Ministry of Health. Kenya AIDS Strategic Framework II.
- 663 26. Republic of Kenya Ministry of Health. National Strategic Plan for Tuberculosis,
- 664 Leprosy and Lung Health. 2019.
- 665 27. Adhikari B, Mishra SR, Schwarz R. Transforming Nepal's primary health care delivery
- 666 system in global health era: addressing historical and current implementation challenges.
- 667 Globalization and Health. $2022;18(1):8.$
- 668 28. Acharya KP, Wilson RT. Antimicrobial Resistance in Nepal. Front Med (Lausanne). 669 2019;6:105. Republic of Kenya Ministry of Health. Kenya AIDS Strategic Framework II.

Republic of Kenya Ministry of Health. National Strategic Plan for Tuberculosis,

perosy and Lung Health. 2019.

Adhikari B, Mishra SP, Schwarz R. Tr
- 670 29. The Fleming Fund. A Protocol for Active AMR Surveillance in Poultry. 2019.
- 671 30. OptiDx. OptiDx [Available from: [https://www.optidx.org/.](https://www.optidx.org/)
- 672 31. FIND. Optimizing TB diagnostic networks to improve patient access to quality TB
- 673 diagnosis and treatment 2018 [Available from: [https://nltp.co.ke/wp-](https://nltp.co.ke/wp-content/uploads/2020/11/DXNetwork-Optimisation_FIND_Kenya_FINAL_01DEC18.pdf)
- 674 [content/uploads/2020/11/DXNetwork-Optimisation_FIND_Kenya_FINAL_01DEC18.pdf.](https://nltp.co.ke/wp-content/uploads/2020/11/DXNetwork-Optimisation_FIND_Kenya_FINAL_01DEC18.pdf)

- 676
- 677
- 678

Supporting information

- **S1 Table.** Recommended bacteriology sample referral system for hospitals in Bungoma County
- **S2 Table.** Distance and cost savings across optimized scenarios for the second tier of network
- 682 in Nepal for human health (AMR isolate referrals to the National Public Health Laboratory)
- AMR, antimicrobial resistance; NPHL, National Public Health Laboratory; TB, tuberculosis; VL,
- viral load.
- **S3 Table.** Distance and cost savings across optimized scenarios for the second tier of network
- 686 in Kenya (AMR isolate referrals to the National Microbiology Reference Laboratory)
- **S1 Fig.** Isolate referrals at baseline in Kenya
- **S2 Fig.** Baseline sample referral network for human health in Kenya Nepal for human health (AMR isolate referrals to the National Public Health Laboratory)
MR, antimicrobial resistance; NPHL, National Public Health Laboratory; TB, tuberculosis; VL,
ral load.
3 Table. Distance and cost sa
- **S3 Fig.** Optimized isolate referral system in Kenya recommended by model
- **S4 Fig.** Recommended animal health sample referral system for isolates in Nepal

Health facility to AMR site linkages

AMR site to NMRL linkages

